DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa Pipeline Landscape

Los Angeles, USA, June 30, 2021 (GLOBE NEWSWIRE) — DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa Pipeline Landscape 

The Dystrophic Epidermolysis bullosa clinical pipeline comprises 20+ notable therapeutic agents in different stages of clinical development varying from Gene therapies, Cell therapies, RNA‐targeting therapy, Protein therapies, Topical therapies, and Small molecules.

DelveInsight’s ‘Dystrophic Epidermolysis Bullosa (DEB) Pipeline Insights’ report presents a complete picture of the available therapies, Dystrophic Epidermolysis Bullosa emerging therapies in different phases of clinical development, key companies working in the Dystrophic Epidermolysis Bullosa pipeline domain, and future potential of the space. 

Some of the focal points picked from the Dystrophic Epidermolysis Bullosa Pipeline report:

• Exhaustive analysis of the Dystrophic Epidermolysis Bullosa Pipeline demonstrates opportunities and scope in the future with the involvement of 20+ key players and 20+ key therapies.
• Key Dystrophic Epidermolysis Bullosa pipeline candidates such as genetically corrected cultured epidermal autograft, INM-755, B-VEC, FCX-007, AGLE-102, PTR-01, FCX-007, and others are under investigation in different phases of clinical trials for the treatment of Dystrophic Epidermolysis Bullosa. 
• The entry of novel therapeutics is expected to boost the Dystrophic Epidermolysis Bullosa treatment market in the coming years.
• Key prominent pharma players including Holostem Terapie Avanzate, InMed Pharmaceuticals, Krystal biotech, Castle Creek Biosciences, Zikani Therapeutics, Aegle Therapeutics, Phoenix Tissue Repair, among others are actively involved in strengthening the Dystrophic Epidermolysis Bullosa pipeline portfolio. 
• DelveInsight estimates that late-stage products such as EB-101, FCX-007, and B-VEC will have a major impact on the Dystrophic Epidermolysis Bullosa treatment market.
• Castle Creek Biosciences is developing FCX-007, a disease-modifying, autologous cell-based gene therapy to address the deficiency of functional type VII collagen protein (COL7) in patients with autosomally recessive or dominant dystrophic epidermolysis bullosa. The US Food and Drug Administration has granted Orphan Drug designation to FCX-007 for the treatment of Dystrophic Epidermolysis Bullosa, which includes RDEB. In addition, FCX-007 has been granted Rare Pediatric Disease designation, Fast Track designation, and Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA for treatment of recessive dystrophic EB (RDEB).
• EB-101 (Abeona Therapeutics) is an autologous, gene-corrected cell therapy for RDEB, a rare connective tissue disorder without an approved treatment in which patients suffer from severe epidermal wounds that impact the length and quality of their lives. The therapy is currently in the phase 3 stage of development to treat Dystrophic Epidermolysis Bullosa. 
• Phoenix Tissue Repair is advancing an investigational therapy known as PTR-01, a systemic recombinant collagen type VII (rC7) for the treatment of Recessive Dystrophic Epidermolysis Bullosa. rC7 is a potentially disease-modifying drug that is delivered intravenously to patients, replacing defective collagen type VII with healthy collagen at the sites where it is needed.

Request for Sample to know more about the therapies expected to make grab the maximum patient pool @ Dystrophic Epidermolysis Bullosa Emerging Therapies and Forecast 

The Dystrophic Epidermolysis Bullosa Pipeline reports offer a holistic scenario of the ongoing clinical trials, partnerships taking place in the domain, recent happenings in space, and growth prospects across the Dystrophic Epidermolysis Bullosa domain.

Dystrophic Epidermolysis Bullosa: Overview

Epidermolysis Bullosa (EB) is a group of inherited disorders that causes blistering, which in several cases can be life-threatening to newborns and infants. It predominantly affects the skin and mucous membrane. A subtype of Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa (DEB) is characterized by the site of blister formation in the lamina densa within the basement membrane zone and the upper dermis. 

Discover more about the disease, treatments, and pipeline therapies @ DEB Pipeline Assessment 

Dystrophic Epidermolysis Bullosa Pipeline Drugs 

Request for Sample to know more @ Dystrophic Epidermolysis Bullosa Pipeline Analysis, Key Companies, and Futuristic Trends 

Dystrophic Epidermolysis Bullosa Therapeutics Assessment 

The Dystrophic Epidermolysis Bullosa Pipeline report presents a kaleidoscopic view of the DEB emerging novel therapies segmented by Stage, Product Type, Route of Administration, Molecule Type, Target, and Mechanism of Action.

By Product Type

By Stage

• Discovery 
• Pre-clinical
• IND
• Phase I
• Phase II
• Phase III
• Pre-registration

By Molecule Type 

• Cell therapy
• Peptides
• Small interfering RNA
• Small molecule
• Gene therapy

By Route of Administration

• Oral
• Intradermal
• Intravenous
• Topical

By Mechanism of Action

• Collagen type VII replacements
• Gene Transference
• RNA interference
• Cannabinoid receptor agonists
• Ribosomal RNA modulators

By Targets

• Cannabinoid receptor 
• Caspase 1 
• Interleukin 1 beta 
• Serine Protease targeted therapy

For rich insights into merging therapies and assessment, visit Dystrophic Epidermolysis Bullosa Pipeline: Emerging Novel Therapies 

Scope of the Dystrophic Epidermolysis Bullosa Pipeline Report

Coverage: Global
Key Players: Holostem Terapie Avanzate, InMed Pharmaceuticals, Krystal biotech, Castle Creek Biosciences, Zikani Therapeutics, Aegle Therapeutics, Phoenix Tissue Repair, and Abeona Therapeutics among others
Key Dystrophic Epidermolysis Bullosa Pipeline Therapies: AGLE 102, PTR-01, FCX-007, EB-101, RGN-137, INM-755, TXA127, and B-VEC among others.
Discover more about the report offerings @ DEB Emerging Therapies, Treatments, and Ongoing Clinical Trials 

Table of Contents 

Learn more about the report offerings @ Dystrophic Epidermolysis Bullosa Pipeline Therapies and Emerging Trends 

Get in touch with our Business executive for Regulatory Analysis, Licensing Services, and Consulting Solutions 

Related Reports

Corneal Endothelial Dystrophy Market
DelveInsight’s ‘Corneal Endothelial Dystrophy (CED) Market Insights, Epidemiology, and Market Forecast—2030’ report with a comprehensive analysis of epidemiology, emerging therapies, and key companies such as Aerie Pharmaceuticals, Kowa Pharmaceuticals, Trefoil Therapeutics, among others. 

Dystrophic Epidermolysis Bullosa Market
DelveInsight’s “Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast-2030” report.

Recessive Dystrophic Epidermolysis Market
DelveInsight’s “Recessive Dystrophic Epidermolysis Market Insights, Epidemiology, and Market Forecast-2030” report. 

Cone Rod Dystrophies Market
DelveInsight’s “Cone-Rod Dystrophies Market Insights, Epidemiology, and Market Forecast-2030” report.

Corneal Dystrophy Market
DelveInsight’s “Corneal Dystrophy – Market Insights, Epidemiology, and Market Forecast-2030” report.

Browse through our posts 

Hepatitis D Market Outlook
Novel Therapies Fueling Epidermolysis Bullosa Market Size
 ABSSSI Pipeline Therapies 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

For more insights, visit Pharma, Healthcare, and Biotech News